How Long Might Pain Relief Last After an A2M Knee Injection?
Published November 16, 2026
Protocol: 7 steps in this guide
- Onset of relief versus duration of relief
- What the trial measured at six weeks
- What the trial measured at twelve weeks
- Why improvement within one group cannot establish duration
- What longer-term comparative data are missing
- What a completed single-group pilot can and cannot show
- Questions to ask about repeat injections and follow-up
Nobody knows yet. The one published randomized trial followed patients for 12 weeks after a single injection, so it cannot say whether any relief lasts six months, a year or longer. Within those 12 weeks, the authors described the A2M benefit as a “modest improvement in knee pain and function at 6-week follow-up,” and the amount of improvement did not differ significantly from platelet-rich plasma (PRP) or a corticosteroid. A clinic that promises relief for a set number of months is going beyond the published evidence.
Onset of relief versus duration of relief
Two different questions hide in “how long does it last.” Onset is how soon relief starts, if it does. Duration is how long it lasts once it starts. A trial can say something about onset at its first check-in and about duration only up to its last one. After the last measurement, the evidence is silent, not positive.
What the trial measured at six weeks
The trial is Thompson and colleagues, Bulletin of the Hospital for Joint Diseases (2024): adults with Kellgren-Lawrence grade 2 or 3 knee osteoarthritis received one injection of an A2M-rich PRP concentrate, PRP or methylprednisolone, with pain and function measured at baseline, 6 weeks and 12 weeks. The authors’ conclusion places the A2M benefit at six weeks and describes it as modest and as appearing “inconsistently across PRO measures” (patient-reported outcome measures), meaning it did not show up on every questionnaire.
What the trial measured at twelve weeks
The abstract reports that by 12 weeks the A2M group showed significant improvement from baseline on several scores, while the PRP group showed none and the steroid group improved on one score only. A 2025 narrative review in the American Journal of Veterinary Research, Evidence for alpha-2-macroglobulin as an orthobiologic osteoarthritis therapy, describes the steroid group’s improved scores as “commensurate to baseline at 12 weeks.” Most important, the changes from baseline to 12 weeks “did not significantly differ between the three groups.” The full results are covered in what research shows about A2M injections for knee osteoarthritis.
| Time point | What the published trial shows |
|---|---|
| Baseline | Measured before injection |
| 6 weeks | Authors describe modest, inconsistent improvement with A2M, similar to PRP and steroid |
| 12 weeks | Within-group changes reported; no significant difference between groups |
| 3 to 6 months | Not established: not measured |
| 6 to 12 months | Not established: not measured |
| Beyond 12 months | Not established: not measured |
Why improvement within one group cannot establish duration
Seeing a group improve over 12 weeks does not tell you how much of that improvement came from A2M. Symptoms in knee osteoarthritis can change over time, and every group in the trial received an injection. The between-group comparison tests whether A2M-rich PRP improved outcomes more than PRP or corticosteroid, and it showed no significant difference at 12 weeks. That is not proof that A2M has no effect: a small trial against active treatments can miss a real difference, and with no placebo group it cannot measure how large an A2M-specific effect is or how long it lasts. How trial design affects this is explained in the difference between a placebo-controlled trial and an observational study, and how to judge whether a change is large enough to matter in what clinically meaningful improvement means in a joint pain study.
What longer-term comparative data are missing
To know how long A2M relief lasts, a study would need to follow patients for six months or more and compare A2M with a control group over the same period. The veterinary review describes a single published human trial, and that trial stopped at 12 weeks. No published comparison covers the months after that.
What a completed single-group pilot can and cannot show
Mayo Clinic’s pilot study of autologous A2M-rich plasma in moderate knee osteoarthritis (NCT06329492) is designed to follow patients longer. Its ClinicalTrials.gov record lists pain and function questionnaires before treatment and at 1, 2 and 6 weeks and 3, 6, 9 and 12 months, with adverse events as the primary outcome. The record lists 20 as the actual enrollment, describes a single group with no comparison arm, and shows the study as completed in February 2026, with no results posted on the registry. When results appear, they may show how scores changed over a year in those participants. Because everyone received A2M, they still will not show how much of any change was due to A2M rather than time or the experience of treatment.
Questions to ask about repeat injections and follow-up
If a clinic offers an A2M injection, ask:
- What evidence supports the duration of relief you are describing, and how long were patients followed?
- Is a repeat injection planned, and on what evidence is the interval based?
- How will my response be measured, and when will we decide whether it worked?
- What will a second injection cost? Pricing is covered in how much A2M joint injections cost.
The published trial gave one injection, so it does not address repeat schedules. The visit itself is described in what happens during an A2M injection appointment.
How long pain relief might last after an A2M knee injection is unknown, because the only published randomized trial stopped at 12 weeks and found no significant difference from PRP or a steroid, so any promise of relief lasting months is not supported by current evidence.
Cells linked to this one
This guide leads on to
- D4 What Does Research Show About A2M Injections for Knee Osteoarthritis?
- I8 What Is the Difference Between a Placebo-Controlled Trial and an Observational Study?
- I9 What Does Clinically Meaningful Improvement Mean in a Joint Pain Study?
- D9 How Much Do A2M Joint Injections Cost?
- D7 What Happens During an A2M Injection Appointment?
Add a remark